The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics
Open accessAbstract
Purpose: We aim to identify genetic variation, in addition to the UGT1A1*28 polymorphism, that can explain the variability in irinotecan (CPT-11) pharmacokinetics and neutropenia in cancer patients. Patients and Methods: Pharmacokinetic, genetic, and clinical data were obtained from 85 advanced cancer patients treated with single-agent CPT-11 every 3 weeks at doses of 300 mg/m 2 (n = 20) and 350 mg/m 2 (n = 65). Forty-two common variants were genotyped in 12 candidate genes of the CPT-11 pathway using several methodologies. Univariate and multivariate models of absolute neutrophil count (ANC) nadir and pharmacokinetic parameters were evaluated. Results: Almost 50% of the variation in ANC nadir is explained by UGT1A1*93, ABCC1 IVS11 –48C>T, SLCO1B1*1b, ANC baseline levels, sex, and race (P < .0001). More than 40% of the variation in CPT-11 area under the curve (AUC) is explained by ABCC2 –24C>T, SLCO1B1*5, HNF1A 79A>C, age, and CPT-11 dose (P < .0001). Almost 30% of the variability in SN-38 (the active metabolite of CPT-11) AUC is explained by ABCC1 1684T>C, ABCB1 IVS9 –44A>G, and UGT1A1*93 (P = .004). Other models explained 17%, 23%, and 27% of the variation in APC (a metabolite of CPT-11), SN-38 glucuronide (SN-38G), and SN-38G/SN-38 AUCs, respectively. When tested in univariate models, pretreatment total bilirubin was able to modify the existing associations between genotypes and phenotypes. Conclusion: On the basis of this exploratory analysis, common polymorphisms in genes encoding for ABC and SLC transporters may have a significant impact on the pharmacokinetics and pharmacodynamics of CPT-11. Confirmatory studies are required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
Innocenti, F., Undevia, S. D., Iyer, L., Xian Chen, P., Das, S., Kocherginsky, M., Karrison, T., Janisch, L., Ramírez, J., Rudin, C. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.173 · Cited by 964
Self-citationBeutler, E., Gelbart, T., & Demina, A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8170 · Cited by 853
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
Iyer, L., Das, S., Janisch, L., Wen, M., Ramírez, J., Karrison, T., Fleming, G. F., Vokes, E. E., Schilsky, R. L., & Ratain, M. J. (2002) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500072 · Cited by 720
Self-citationIyer, L., King, C. D., Whitington, P. F., Green, M. D., Roy, S. K., Tephly, T. R., Coffman, B. L., & Ratain, M. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci915 · Cited by 686
Self-citationSLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
Pasanen, M. K., Neuvonen, M., Neuvonen, P. J., & Niemi, M. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230416.82349.90 · Cited by 470
UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Dose Matters
Hoskins, J. M., Goldberg, R. M., Qu, P., Ibrahim, J. G., & McLeod, H. L. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm115 · Cited by 469
SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid
Tornio, A., Vakkilainen, J., Neuvonen, M., Backman, J. T., Neuvonen, P. J., & Niemi, M. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000148 · Cited by 409
Pharmacogenetics of warfarin: current status and future challenges
Wadelius, M., & Pirmohamed, M. (2007) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500417 · Cited by 330
Strassburg, C. P., Oldhafer, K., Manns, M. P., & Tukey, R. H. (1997) · Molecular Pharmacology · doi:10.1124/mol.52.2.212 · Cited by 275
Irinotecan pathway genotype analysis to predict pharmacokinetics.
Mathijssen, R. H. J., Marsh, S., Karlsson, M. O., Xie, R., Baker, S. D., Verweij, J., Sparreboom, A., & McLeod, H. L. (2003) · PubMed · Cited by 258
SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin
NIEMI, M., PASANEN, M., & NEUVONEN, P. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.06.010 · Cited by 250
Leabman, M. K., Huang, C. C., DeYoung, J., Carlson, E. J., Taylor, T. R., de la Cruz, M., Johns, S. J., Stryke, D., Kawamoto, M., Urban, T. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0730857100 · Cited by 220
Self-citationHan, J., Lim, H., Yoo, Y., Shin, E. S., Park, Y. H., Lee, S. Y., Lee, J., Lee, D. H., Kim, H. T., & Lee, J. S. (2007) · Cancer · doi:10.1002/cncr.22760 · Cited by 195
Irinotecan-induced Diarrhea: Functional Significance of the Polymorphic ABCC2 Transporter Protein
de Jong, F. A., Scott-Horton, T. J., Kroetz, D. L., McLeod, H. L., Friberg, L. E., Mathijssen, R. H., Verweij, J., Marsh, S., & Sparreboom, A. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100019 · Cited by 171
Self-citationHaenisch, S., Zimmermann, U., Dazert, E., Wruck, C. J., Dazert, P., Siegmund, W., Kroemer, H. K., Warzok, R. W., & Cascorbi, I. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500403 · Cited by 168
O'Dwyer, P. J., & Catalano, R. B. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3031 · Cited by 166
Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups.
Innocenti, F., Grimsley, C., Das, S., Ramírez, J., Cheng, C., Kuttab-Boulos, H., Ratain, M. J., & Rienzo, A. D. (2002) · Pharmacogenetics · doi:10.1097/00008571-200212000-00006 · Cited by 159
Self-citationMoriya, Y., Nakamura, T., Horinouchi, M., Sakaeda, T., Tamura, T., Aoyama, N., Shirakawa, T., Gotoh, A., Fujimoto, S., Masafumi, M., et al. (2002) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.25.1356 · Cited by 151
Haenisch, S., Zimmermann, U., Dazert, E., Wruck, C. J., Dazert, P., Siegmund, S., Kroemer, H. K., Warzok, R., & Cascorbi, I. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500409 · Cited by 135
Body-Surface Area–Based Dosing Does Not Increase Accuracy of Predicting Cisplatin Exposure
de Jongh, F. E., Verweij, J., Loos, W. J., de Wit, R., de Jonge, M. J. A., Planting, A. S. T., Nooter, K., Stoter, G., & Sparreboom, A. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.17.3733 · Cited by 130
UGT1A1 Polymorphism Can Predict Hematologic Toxicity in Patients Treated with Irinotecan
Côté, J.-F., Kirzin, S., Kramar, A., Mosnier, J., Diébold, M.-D., Soubeyran, I., de Lajarte‐Thirouard, A., Sèlves, J., Laurent‐Puig, P., & Ychou, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2290 · Cited by 129
Conrad, S., Kauffmann, H.-M., Ito, K., Leslie, E. M., Deeley, R. G., Schrenk, D., & Cole, S. P. C. (2002) · Pharmacogenetics · doi:10.1097/00008571-200206000-00008 · Cited by 110
Impact of Body-Size Measures on Irinotecan Clearance: Alternative Dosing Recommendations
Mathijssen, R. H. J., Verweij, J., de Jonge, M. J. A., Nooter, K., Stoter, G., & Sparreboom, A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.81 · Cited by 103
Xiang, X., Jada, S. R., Li, H. H., Fan, L., Tham, L. S., Wong, C. I., Lee, S. C., Lim, R. S. C., Zhou, Q. Y., Goh, B. C., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230420.05221.71 · Cited by 93
Han, J., Lim, H., Shin, E., Yoo, Y.-K., Park, Y. H., Lee, J.-E., Kim, H. T., & Lee, J. S. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.07.019 · Cited by 92
Freyer, G., Rougier, P. R., Bugat, R., Droz, J., Marty, M. E., Bleiberg, H., Mignard, D., Awad, L., Herait, P., Culine, S., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1303 · Cited by 91
Haenisch, S., May, K. E., Wegner, D., Caliebe, A., Cascorbi, I., & Siegmund, W. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f974b7 · Cited by 88
Conrad, S., Kauffmann, H.-M., Ito, K., Deeley, R. G., Cole, S. P. C., & Schrenk, D. (2001) · Journal of Human Genetics · doi:10.1007/s100380170017 · Cited by 87
Ramchandani, R. P., Wang, Y., Booth, B. P., Ibrahim, A., Johnson, J. R., Rahman, A., Mehta, M., Innocenti, F., Ratain, M. J., & Gobburu, J. V. S. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006295060 · Cited by 85
Self-citationLétourneau, I. J., Deeley, R. G., & Cole, S. P. C. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000173484.51807.48 · Cited by 81
Insights, Challenges, and Future Directions in Irinogenetics
Kim, T., & Innocenti, F. (2007) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318068623b · Cited by 70
Self-citationLeslie, E. M., Létourneau, I. J., Deeley, R. G., & Cole, S. P. C. (2003) · Biochemistry · doi:10.1021/bi027076n · Cited by 68
Irinogenetics: What Is the Right Star?
Innocenti, F., Vokes, E. E., & Ratain, M. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.2464 · Cited by 58
Self-citationMeyerhardt, J. A., Kwok, A., Ratain, M. J., McGovren, J. P., & Fuchs, C. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.043 · Cited by 54
Self-citationFlat-Fixed Dosing of Irinotecan
de Jong, F. A., Mathijssen, R. H. J., Xie, R., Verweij, J., & Sparreboom, A. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0591 · Cited by 52
Pharmacogenetic Pathway Analysis of Irinotecan
Rosner, G., Panetta, J. C., Innocenti, F., & Ratain, M. J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.63 · Cited by 48
Self-citationSearching for Tissue-Specific Expression Pattern-Linked Nucleotides of UGT1A Isoforms
Zhang, W., Liu, W., Innocenti, F., & Ratain, M. J. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000396 · Cited by 30
Self-citation
Cited by
Niemi, M., Pasanen, M. K., & Neuvonen, P. J. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002857 · Cited by 633
Circadian Timing in Cancer Treatments
Lévi, F., Okyar, A., Dulong, S., Innominato, P. F., & Clairambault, J. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094626 · Cited by 476
Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management
Stein, A., Voigt, W., & Jordan, K. (2010) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834009355164 · Cited by 431
“SN-38 in the active form into the blood and in the glucuronidated form into the bile (Figure 1) [De Jong et al. 2007; Han et al. 2009; Innocenti et al. 2009].”
Backgroundde Man, F. M., Goey, A. K. L., van Schaik, R. H. N., Mathijssen, R. H. J., & Bins, S. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0644-7 · Cited by 421
“In addition, neutropenia appears to occur more frequently in females [174].”
BackgroundDrug Transporters in Drug Efficacy and Toxicity
DeGorter, M. K., Xia, C. Q., Yang, J. J., & Kim, R. B. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134529 · Cited by 359
Metadata
- Authors
- Innocenti, F., Kroetz, D. L., Schuetz, E., Dolan, M. E., Ramírez, J., Relling, M., Chen, P., Das, S., Rosner, G. L., & Ratain, M. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-06-01
- Volume
- 27
- Issue
- 16
- Pages
- 2604-2614
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2100917151
- Cited by
- 262
- References
- 38
- FWCI
- 23.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.